Send me real-time posts from this site at my email

Why uniQure Stock Is Crashing Today

What happened

Shares of uniQure N.V. (NASDAQ: QURE) are crashing today, down by 32.6% as of 11:19 a.m. ET. The steep decline came after the gene therapy specialist provided its second-quarter update Monday morning.

Investors weren't all that interested in uniQure's financial results. The company's only revenue is from collaborations. uniQure reported a net loss in Q2 of $39.1 million, or $0.84 per share, on revenue of just $0.5 million.

So why did the biotech stock plunge so much? uniQure announced the postponement of adding higher-dose procedures in a phase 1/2 study of AMT-130 in treating early-stage Huntington's disease.

So what

uniQure only has two programs in clinical testing, one of which is AMT-130. Any bad news for the experimental gene therapy, therefore, will almost certainly rattle investors.

In July, the company reported that three of 14 patients treated with a higher dose of AMT-130 experienced unexpected severe adverse reactions. As a result, uniQure decided to delay any additional higher-dose procedures in the study until it can implement additional monitoring and treatment plans, as well as complete a safety review.

Importantly, there haven't been any reports of severe adverse events related to AMT-130 in patients receiving lower doses of the experimental therapy. uniQure doesn't expect any impact of its delay related to higher-dose procedures on the timing of announcing results from the lower-dose procedures.

Now what

uniQure expects to complete its safety review early in Q4 of this year. The company also continues to anticipate reporting data from one- to two-year follow-ups on both low- and high-dose cohorts of its AMT-130 clinical study in Q2 of 2023.

10 stocks we like better than uniQure
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and uniQure wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of July 27, 2022

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Source

Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue